Toward an Understanding of Changes in Diversity Associated with Fecal Microbiome Transplantation Based on 16S rRNA Gene Deep Sequencing

Dea Shahinas, Michael Silverman, Taylor Sittler, Charles Y. Chiu, Peter Kim, Emma Allen‐Vercoe, J. Scott Weese, Andrew Wong, Donald E. Low, Dylan R. Pillai

mBio · 2012 · 193 citations · 39 references

DOIFull text

Open access

Concepts

TL;DR

Clostridium difficile infection causes widespread antibiotic‑associated diarrhea, with up to 30 % of patients experiencing recurrent disease that is often refractory to antibiotics, prompting clinicians to use fecal microbiome transplantation, which has a reported success rate exceeding 90 % and is considered an effective, safe, and inexpensive alternative. The study aims to identify specific bacterial taxa or products that could serve as a probiotic treatment for CDI through genus‑ and species‑level analysis. The authors performed 16S rRNA deep sequencing on pre‑ and post‑transplant stool samples from six CDI patients, using donor stool from relatives that was rigorously screened for pathogens. Clinical cure of CDI correlated with increased microbial diversity and richness, and analysis identified a mixture of Bacteroidetes and Firmicutes species that could serve as a probiotic.

Abstract

Fecal microbiome transplantation by low-volume enema is an effective, safe, and inexpensive alternative to antibiotic therapy for patients with chronic relapsing Clostridium difficile infection (CDI). We explored the microbial diversity of pre- and posttransplant stool specimens from CDI patients (n = 6) using deep sequencing of the 16S rRNA gene. While interindividual variability in microbiota change occurs with fecal transplantation and vancomycin exposure, in this pilot study we note that clinical cure of CDI is associated with an increase in diversity and richness. Genus- and species-level analysis may reveal a cocktail of microorganisms or products thereof that will ultimately be used as a probiotic to treat CDI. IMPORTANCE Antibiotic-associated diarrhea (AAD) due to Clostridium difficile is a widespread phenomenon in hospitals today. Despite the use of antibiotics, up to 30% of patients are unable to clear the infection and suffer recurrent bouts of diarrheal disease. As a result, clinicians have resorted to fecal microbiome transplantation (FT). Donor stool for this type of therapy is typically obtained from a spouse or close relative and thoroughly tested for various pathogenic microorganisms prior to infusion. Anecdotal reports suggest a very high success rate of FT in patients who fail antibiotic treatment (>90%). We used deep-sequencing technology to explore the human microbial diversity in patients with Clostridium difficile infection (CDI) disease after FT. Genus- and species-level analysis revealed a cocktail of microorganisms in the Bacteroidetes and Firmicutes phyla that may ultimately be used as a probiotic to treat CDI.

References

39